One-dose Sputnik Light set for rollout in September

Mumbai: India’s immunisation plan against Covid-19 may get bolstered soon with the rollout of locally manufactured single-dose Sputnik Light in September. Panacea Biotec, which had earlier partnered Russian Direct Investment Fund (RDIF), has submitted the dossier for seeking emergency-use authorisation to India’s drug regulator recently, sources told TOI. The vaccine, which will be available in limited quantities initially, is expected to be priced around Rs 750.

Till now, the immunisation programme has been using imported two-dose Sputnik V, rolled out by Hyderabad-based Dr Reddy’s, RDIF’s exclusive distribution partner for India.

Shortages in supply of the two-dose Sputnik V could be resolved as early as the month-end, with Dr Reddy’s ramping up supplies, sources added. The full rollout of the Sputnik V vaccine was put on hold and is hence lagging, as its imports from Russia were impacted in June. Around five lakh doses of Sputnik V’s component 2 vaccine, which have been imported, could be rolled out in India soon.

We are also working closely with our partners in India for manufacturing readiness. We expect that locally manufactured doses are likely to be available from the September-October period’’, a Dr Reddy’s spokesperson said.

Sputnik Light, developed by Russia’s Gamaleya Institute and backed by RDIF, received emergency use authorisation in Russia in May. It is perceived by experts as more ‘suitable’, given the task of vaccinating a large population even as a possible third wave looms. The Sputnik Light jab has demonstrated nearly 80% efficacy, according to analysed data taken 28 days after the injection was administered in a trial in Russia, an RDIF statement said.

  • Related Posts

    • Pharma
    • July 22, 2025
    • 80 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    • Pharma
    • July 16, 2025
    • 479 views
    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

    Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end